<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04687150</url>
  </required_header>
  <id_info>
    <org_study_id>T298/2020</org_study_id>
    <nct_id>NCT04687150</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation and Newly Diagnosed Ulcerative Colitis (UC)</brief_title>
  <acronym>FinUC</acronym>
  <official_title>Fecal Microbiota Transplantation in Newly Diagnosed Ulcerative Colitis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Päijänne Tavastia Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this FinUC study we are trying to find out the efficacy and safety of the Fecal microbiota&#xD;
      transplantation (FMT) in newly diagnosed active ulcerative colitis patients. The study group&#xD;
      with newly diagnosed active ulcerative colitis receive an FMT via colonoscopy from a tested&#xD;
      general donor, frozen and thawed from a fecal bank at week 0 and at week 4 as an enema at the&#xD;
      study nurse´s visit. The control group will be given colored water. The main aim of the FinUC&#xD;
      study is to determine how the FMT change of the gut microbiota composition in newly diagnosed&#xD;
      active ulcerative colitis patients. The other aim is to determine efficacy and mechanisms of&#xD;
      fecal microbiota transplantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized placebo-controlled pilot study. Accrued participants were randomized 1:1 using a computer generated randomization algorithm (www.random.org).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>e</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Modified gut microbiota composition</measure>
    <time_frame>at week 12</time_frame>
    <description>Increased species richness and alfa-diversity</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>The study group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study group with newly diagnosed active ulcerative colitis receive an FMT via colonoscopy from a tested general donor, frozen and thawed from a fecal bank at week 0 and at week 4 as an enema at the study nurse´s visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group will be given colored water at same timepoints</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fecal microbiota transplantation</intervention_name>
    <description>Fecal microbiota transplantation from a tested general donor, frozen and thawed from a fecal bank</description>
    <arm_group_label>The study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Colored water</intervention_name>
    <description>Colored water (placebo)</description>
    <arm_group_label>The control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Over 18 years&#xD;
&#xD;
          -  Active newly diagnosed colitis (Mayo score &lt;11)&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fulminant severe colitis (Mayo score 11-12 or Truelove and Witts criteria)&#xD;
&#xD;
          -  Gastrointestinal infection&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Antibiotic therapy at the baseline&#xD;
&#xD;
          -  On-going probiotic medication&#xD;
&#xD;
          -  Unable to provide signed informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>December 26, 2020</last_update_submitted>
  <last_update_submitted_qc>December 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Kimmo Salminen</investigator_full_name>
    <investigator_title>MD, PhD, Specialist in Gastroenterology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

